PharmaEngine, Inc. (4162.TWO)
TWD 89.0
(-9.92%)
TWD 89.0
(-9.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -860.8 Million TWD | 50.71% |
| 2022 | -1.74 Billion TWD | 18.5% |
| 2021 | -2.14 Billion TWD | -18.16% |
| 2020 | -1.81 Billion TWD | -2953.2% |
| 2019 | -59.4 Million TWD | 83.37% |
| 2018 | -357.19 Million TWD | 37.85% |
| 2017 | -574.73 Million TWD | 68.78% |
| 2016 | -1.84 Billion TWD | -329.49% |
| 2015 | -428.6 Million TWD | 85.2% |
| 2014 | -2.89 Billion TWD | -7.35% |
| 2013 | -2.69 Billion TWD | -67.86% |
| 2012 | -1.6 Billion TWD | -169.28% |
| 2011 | -596.93 Million TWD | -674.51% |
| 2010 | -77.07 Million TWD | -1270.41% |
| 2009 | -5.62 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.27 Billion TWD | -37.61% |
| 2024 Q1 | -927.08 Million TWD | -7.7% |
| 2023 Q1 | -1.92 Billion TWD | -10.33% |
| 2023 Q3 | -1.72 Billion TWD | 13.54% |
| 2023 Q4 | -860.8 Million TWD | 49.97% |
| 2023 FY | -860.8 Million TWD | 50.71% |
| 2023 Q2 | -1.98 Billion TWD | -3.27% |
| 2022 Q1 | -2.2 Billion TWD | -2.98% |
| 2022 Q3 | -1.72 Billion TWD | 23.4% |
| 2022 Q4 | -1.74 Billion TWD | -1.54% |
| 2022 FY | -1.74 Billion TWD | 18.5% |
| 2022 Q2 | -2.24 Billion TWD | -1.75% |
| 2021 Q2 | -2.94 Billion TWD | -22.22% |
| 2021 Q3 | -2.54 Billion TWD | 13.37% |
| 2021 Q4 | -2.14 Billion TWD | 15.91% |
| 2021 Q1 | -2.4 Billion TWD | -32.72% |
| 2021 FY | -2.14 Billion TWD | -18.16% |
| 2020 Q4 | -1.81 Billion TWD | -566.49% |
| 2020 Q3 | -272.12 Million TWD | 3.44% |
| 2020 FY | -1.81 Billion TWD | -2953.2% |
| 2020 Q1 | -56.86 Million TWD | 4.26% |
| 2020 Q2 | -281.81 Million TWD | -395.55% |
| 2019 Q3 | -132.58 Million TWD | -7.88% |
| 2019 Q4 | -59.4 Million TWD | 55.2% |
| 2019 FY | -59.4 Million TWD | 83.37% |
| 2019 Q1 | -823.43 Million TWD | -130.53% |
| 2019 Q2 | -122.9 Million TWD | 85.07% |
| 2018 Q1 | -132.95 Million TWD | 76.87% |
| 2018 Q4 | -357.19 Million TWD | -313.19% |
| 2018 Q3 | -86.44 Million TWD | 66.75% |
| 2018 Q2 | -259.98 Million TWD | -95.54% |
| 2018 FY | -357.19 Million TWD | 37.85% |
| 2017 Q1 | -1.78 Billion TWD | 2.95% |
| 2017 Q4 | -574.73 Million TWD | 52.4% |
| 2017 Q3 | -1.2 Billion TWD | 23.2% |
| 2017 Q2 | -1.57 Billion TWD | 11.99% |
| 2017 FY | -574.73 Million TWD | 68.78% |
| 2016 Q3 | -1.44 Billion TWD | 8.82% |
| 2016 FY | -1.84 Billion TWD | -329.49% |
| 2016 Q2 | -1.58 Billion TWD | -143.89% |
| 2016 Q1 | -649.9 Million TWD | -51.63% |
| 2016 Q4 | -1.84 Billion TWD | -27.37% |
| 2015 Q3 | -701.21 Million TWD | 76.63% |
| 2015 Q4 | -428.6 Million TWD | 38.88% |
| 2015 Q2 | -3 Billion TWD | -4.84% |
| 2015 Q1 | -2.86 Billion TWD | 1.18% |
| 2015 FY | -428.6 Million TWD | 85.2% |
| 2014 Q3 | -2.69 Billion TWD | -1.02% |
| 2014 Q2 | -2.66 Billion TWD | 0.78% |
| 2014 Q1 | -2.68 Billion TWD | 0.53% |
| 2014 FY | -2.89 Billion TWD | -7.35% |
| 2014 Q4 | -2.89 Billion TWD | -7.66% |
| 2013 Q2 | -1.58 Billion TWD | 0.85% |
| 2013 Q4 | -2.69 Billion TWD | -50.18% |
| 2013 Q3 | -1.79 Billion TWD | -13.19% |
| 2013 Q1 | -1.6 Billion TWD | 0.41% |
| 2013 FY | -2.69 Billion TWD | -67.86% |
| 2012 FY | -1.6 Billion TWD | -169.28% |
| 2012 Q2 | -732.93 Million TWD | -23.74% |
| 2012 Q3 | -1.62 Billion TWD | -121.07% |
| 2012 Q1 | -592.3 Million TWD | 0.77% |
| 2012 Q4 | -1.6 Billion TWD | 0.8% |
| 2011 Q4 | -596.93 Million TWD | 0.0% |
| 2011 FY | -596.93 Million TWD | -674.51% |
| 2010 FY | -77.07 Million TWD | -1270.41% |
| 2009 FY | -5.62 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd | -77.04 Million TWD | -1017.294% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | -264.16 Million TWD | -225.855% |
| Level Biotechnology Inc. | -453.9 Million TWD | -89.645% |
| Sagittarius Life Science Corp | -120.57 Million TWD | -613.949% |
| NeoCore Technology Co., Ltd. | -196.39 Million TWD | -338.3% |
| TaiMed Biologics Inc. | 499.84 Million TWD | 272.214% |
| GlycoNex Incorporation | -148.56 Million TWD | -479.407% |
| VBI | -25.31 Million TWD | -3300.253% |
| GeneReach Biotechnology Corp. | 40.26 Million TWD | 2237.804% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 137.99 Million TWD | 723.797% |
| SynCore Biotechnology Co.,Ltd | -262.58 Million TWD | -227.824% |
| Genomics BioSci & Tech. Co.,Ltd. | 30.57 Million TWD | 2915.122% |
| Visgeneer Inc. | 31.28 Million TWD | 2851.592% |
| Mycenax Biotech Inc. | 207 Million TWD | 515.831% |
| Sunmax Biotechnology Co., Ltd. | -680.6 Million TWD | -26.477% |
| G&E Herbal Biotechnology Co., Ltd. | -134.25 Million TWD | -541.188% |
| Neith Corporation | -150.31 Million TWD | -472.685% |
| Medigen Vaccine Biologics Corporation | 621.53 Million TWD | 238.497% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -57.65 Million TWD | -1392.955% |
| Enimmune corporation | -314.15 Million TWD | -174.004% |
| TaiRx, Inc. | -147.86 Million TWD | -482.142% |
| CHO Pharma, Inc. | -203.79 Million TWD | -322.395% |
| EirGenix Inc. | -4.58 Billion TWD | 81.238% |
| BioLASCO Taiwan Co., Ltd. | -84.76 Million TWD | -915.547% |
| Sunny Pharmtech Inc. | 120.87 Million TWD | 812.171% |
| Lin BioScience, Inc. | -3.21 Billion TWD | 73.252% |
| BioGend Therapeutics Co., Ltd. | -317.41 Million TWD | -171.191% |
| Feng Chi Biotech Corp. | -19.81 Million TWD | -4244.663% |
| Bio Preventive Medicine Corp. | 31.8 Million TWD | 2806.177% |
| Lukas Biomedical Inc. | 50.75 Million TWD | 1796.006% |
| RBC Bioscience Corporation | 422.18 Million TWD | 303.894% |
| BiOptic Inc. | 12.59 Million TWD | 6936.15% |
| BRIM Biotechnology, Inc. | -944.4 Million TWD | 8.852% |
| Shine-On BioMedical Co.,Ltd. | -101.48 Million TWD | -748.204% |
| Great Novel Therapeutics Biotech & Medicals | -165.17 Million TWD | -421.146% |
| Syngen Biotech Co.,Ltd. | 314.87 Million TWD | 373.383% |
| Advagene Biopharma Co., Ltd. | -64.32 Million TWD | -1238.3% |
| NaviFUS Corp. | -123.12 Million TWD | -599.111% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 74.05 Million TWD | 1262.453% |
| Sinew Pharma Inc. | -160.34 Million TWD | -436.847% |
| Andros Pharmaceuticals Co.,Ltd | -241.89 Million TWD | -255.863% |
| Greenyn Biotechnology Co., Ltd | -337.37 Million TWD | -155.149% |
| Lumosa Therapeutics Co., Ltd. | -412.63 Million TWD | -108.611% |
| AP Biosciences Inc | -196.52 Million TWD | -338.008% |
| Medigen Biotechnology Corp. | 688.73 Million TWD | 224.984% |
| 3D Global Biotech Inc. | -11.43 Million TWD | -7426.519% |
| Pharmosa Biopharm Inc. | -829.69 Million TWD | -3.751% |
| Intech Biopharm Corporation | 1.35 Billion TWD | 163.419% |
| Oneness Biotech Co., Ltd. | -414.87 Million TWD | -107.485% |
| Eusol Biotech Co.,Ltd. | -209.33 Million TWD | -311.205% |
| TWi Biotechnology, Inc. | -143.86 Million TWD | -498.353% |
| Ever Supreme Bio Technology Co., Ltd | -330.54 Million TWD | -160.423% |
| TCI GENE Inc. | -689.25 Million TWD | -24.89% |
| MegaPro Biomedical Co., Ltd | -118.93 Million TWD | -623.745% |
| Senhwa Biosciences, Inc. | -1.3 Billion TWD | 34.25% |
| Taiwan Bio Therapeutics Co., Ltd | 20.48 Million TWD | 4302.548% |
| NatureWise Biotech & Medicals Corporation | -101.87 Million TWD | -745.006% |
| Savior Lifetec Corporation | -812.54 Million TWD | -5.94% |
| TaiGen Biopharmaceuticals Holdings Limited | -299.96 Million TWD | -186.967% |
| OBI Pharma, Inc. | -398.22 Million TWD | -116.162% |
| Meribank Biotech Co., Ltd | -365.41 Million TWD | -135.567% |
| Acepodia, Inc. | -6.02 Billion TWD | 85.701% |
| Caliway Biopharmaceuticals Co., Ltd. | -3.4 Billion TWD | 74.695% |